Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

BCAX

Bicara Therapeutics Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • BCAXBicara Therapeutics
    0Calm

    FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

    Signing up patientsPhase 2/3650 patientsMain results: Apr 2028
  • BCAXBicara Therapeutics
    0Calm

    A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

    Signing up patientsPhase 2160 patientsMain results: Mar 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

19 sales (0 not pre-planned) · 0 purchases

  • Cohlhepp RyanPresident, COO & Interim CEO · Sep 8, 2026Sold 14,058 sharesabout $320 thousand · pre-planned
  • Cohlhepp RyanPresident, COO & Interim CEO · Sep 8, 2026Sold 3,442 sharesabout $81 thousand · pre-planned
  • Hyep IvanChief Financial Officer · Aug 10, 2026Sold 12,500 sharesabout $350 thousand · pre-planned
  • Mazumdar ClaireChief Executive Officer · Aug 10, 2026Sold 10,000 sharesabout $280 thousand · pre-planned
  • Cohlhepp RyanPresident and COO · Aug 10, 2026Sold 18,750 sharesabout $525 thousand · pre-planned
  • Mazumdar ClaireChief Executive Officer · Jul 10, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • Signed a major agreementNews report (8-K)Aug 25, 2026
  • Quarterly reportQuarterly report (10-Q)Aug 11, 2026
  • Shared quarterly resultsNews report (8-K)Aug 11, 2026
  • An executive or board member joined or left; Shared information with investorsNews report (8-K)Jul 28, 2026
  • News reportNews report (8-K)Jun 10, 2026

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.
Sold 9,972 sharesabout $283 thousand · pre-planned
  • Mazumdar ClaireChief Executive Officer · Jul 10, 2026Sold 28 sharesabout $831 · pre-planned
  • Cohlhepp RyanPresident and COO · Jul 9, 2026Sold 536 sharesabout $16 thousand · pre-planned
  • Cohlhepp RyanPresident and COO · Jul 8, 2026Sold 22,833 sharesabout $657 thousand · pre-planned
  • Cohlhepp RyanPresident and COO · Jul 8, 2026Sold 4,306 sharesabout $128 thousand · pre-planned
  • Cohlhepp RyanPresident and COO · Jul 8, 2026Sold 1,075 sharesabout $33 thousand · pre-planned
  • Hyep IvanChief Financial Officer · Jul 8, 2026Sold 22,757 sharesabout $651 thousand · pre-planned
  • Hyep IvanChief Financial Officer · Jul 8, 2026Sold 4,413 sharesabout $132 thousand · pre-planned
  • Hyep IvanChief Financial Officer · Jul 8, 2026Sold 830 sharesabout $25 thousand · pre-planned
  • Hyep IvanChief Financial Officer · May 21, 2026Sold 9,200 sharesabout $188 thousand · pre-planned
  • Mazumdar ClaireChief Executive Officer · May 18, 2026Sold 12,022 sharesabout $240 thousand · pre-planned
  • Mazumdar ClaireChief Executive Officer · May 18, 2026Sold 2,978 sharesabout $61 thousand · pre-planned
  • Cohlhepp RyanPresident and COO · May 15, 2026Sold 8,000 sharesabout $162 thousand · pre-planned
  • Cohlhepp RyanPresident and COO · May 15, 2026Sold 4,500 sharesabout $91 thousand · pre-planned
    • Other newsNews report (8-K)
    May 21, 2026
  • Quarterly reportQuarterly report (10-Q)May 11, 2026
  • Shared quarterly resultsNews report (8-K)May 11, 2026